Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
September 2003
Features
Commentary
Putting ALLHAT into Perspective
The media had a field day with the ALLHAT study, but its findings need to be placed into the context of a larger body of evidence.
David B. Nash, MD, MBA, and Janice L. Clarke, RN, BBA
Health Care and Law
Maine’s Plan to Lower Drug Costs for the Uninsured Passes a Major Legal Test
A plan from Maine to reduce health care costs for uninsured patients could become a model for the nation.
Robert I. Field, JD, MPH, PhD
Principles of Antibiotic Formulary Selection for P&T Committees, Part 4: Antimicrobial Side Effects
Dr. Cunha describes some adverse consequences of antimicrobial therapy.
Burke A. Cunha, MD
Continuing Education Credit
Antiretroviral Therapy in HIV-Infected Adults, Part 2: Review of Selected Agents
The authors provide an overview of the major antiretroviral medications used to treat AIDS and HIV infection.
Eli Korner, PharmD, MPH, Mary Ellen Bonk, PharmD, Thomas Ratko, PhD, and Karl A. Matuszewski, MS, PharmD
Departments
Editorial
The Emperor’s New Clothes? A $12 Million Tale
Dr. Matuszewski has several theories as to why we’re
listening to the Leapfrog Group’s advice on CPOE.
Karl A. Matuszewski, MS, PharmD
Prescription Washington
DEA Seeks to Reduce Pharmacy Costs on Ordering Controlled Substances
Stephen Barlas discusses the DEA’s proposal to cut costs on ordering controlled substances.
Stephen Barlas
Medication Errors
Dangers of Peritoneal Dialysis Solutions When Knowledge of Physiology Is Poor
Matthew Grissinger demonstrates why pharmacists need to understand physiology in order to prepare peritoneal dialysis solutions.
Matthew Grissinger, RPh, FASCP
Drug News
New Drugs/Drug News
P&T presents the latest information about approvals, indication changes, industry updates, and news from the FDA.
Drug Forecast
Enfuvirtide: A Novel Agent for Inhibiting the Entry of HIV-1 into Immune Cells
The authors review enfuvirtide (Fuzeon®), a new agent for the treatment of HIV-1 infection.
Nathaniel Eraikhuemen, PharmD, Evans Branch III, PharmD, Naomi Boston, PharmD, Marlon Honeywell, PharmD, and Kevin Sneed, PharmD
P&T Snapshot
The Use of Diuretics in Hypertension
ALLHAT and Diuretics
